Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance
Yi‐Ying Wu(National Defense Medical Center), Yi‐Lin Chiu(National Defense University)
Cited by 24
Related Papers
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Pharmacokinetics and Pharmacodynamics of Lansoprazole in Children with Gastroesophageal Reflux Disease
|Journal of Pediatric Gastroenterology and Nutrition|2002|31
Pharmacokinetics and Pharmacodynamics of Lansoprazole in Children 13 to 24 Months Old With Gastroesophageal Reflux Disease
|Journal of Pediatric Gastroenterology and Nutrition|2007|9